Kimberly Martinez
Adult Health · McMinnville, ORNPI 1083637680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Biogen at 26.6% of the total. 2025 is the largest year on record at $725, more than ten times the $37 reported in 2021.
Across 81 payments — averaging $28.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$609
- Argenx US, Inc.$280
- TG Therapeutics, Inc.$248
- Lilly USA, LLC$199
- Sanofi$133
- AbbVie$109
- plus $716 from 22 others
What the payments were for
- Food & beverage$2,22997%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 26 | $609 |
| Argenx US, Inc. | 4 | $280 |
| TG Therapeutics, Inc. | 6 | $248 |
| Lilly USA, LLC | 4 | $199 |
| Sanofi | 5 | $133 |
| AbbVie | 5 | $109 |
| Microtransponder, Inc. | 1 | $75 |
| Merz Pharmaceuticals, LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| AstraZeneca(2 entities) | 2 | $44 |
| SK Life Science, Inc. | 2 | $44 |
| UCB, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $38 |
| Genentech USA, Inc. | 1 | $31 |
| Novo Nordisk | 1 | $29 |
| EMD Serono, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Banner Life Sciences, LLC | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Novartis | 1 | $17 |
| Livanova USA, Inc. | 1 | $17 |
| CSL Behring | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$150
- VYVGART HYTRULO$125
- TYSABRI$125
- VYVGART$100
How this compares
$2,294 in reported general payments places this provider in the 80th percentile of 96 adult health providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 14 | $123,311 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $106,100 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| Aimovig AutoinjectorErenumab-Aooe | 69 | $51,119 |
| NuedextaDextromethorphan Hbr/Quinidine | 19 | $32,026 |
| Glatiramer Acetate | 14 | $19,414 |
| UbrelvyUbrogepant | 18 | $17,988 |
| Emgality PenGalcanezumab-Gnlm | 18 | $13,792 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $12,406 |
| TopamaxTopiramate | 19 | $11,969 |
| XareltoRivaroxaban | 12 | $7,104 |
| Carbamazepine ErCarbamazepine | 62 | $5,935 |
| Gabapentin | 269 | $5,835 |
| Pregabalin | 88 | $5,459 |
| Levetiracetam | 138 | $4,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $609 | $123,31114 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $46 | $74,59913 claims |
| AbbVieUbrelvy | $109 | $17,98818 claims |
| Johnson & JohnsonXarelto | $18 | $7,10412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 adult health providers in Oregon.
Other adult health in McMinnville
- Lakshi AldredgePortland$393K
- Deborah JonesLake Oswego$44K
- Erin MyklebustPortland$14K
- Yasmine LeePortland$11K
- Terri WarrenPortland$10K
- Brenda BrewerTualatin$7K
- Rachael GreerSeaside$7K
- Julie HinsonSalem$6K
- Linda Picker JohnsonGrants Pass$3K
- Adria ThomasMedford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.